Cochrane · systematic review · CD004920
Antifungal agents for preventing fungal infections in non‐neutropenic critically ill patients
Cortegiani, A, Russotto, V, Maggiore, A, et al. · Cochrane Database of Systematic Reviews · 2016 · Cochrane Library
Emergency and Critical CareAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
5
current version
GRADE rated
5
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 4 · 80%Moderate 1 · 20%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Untargeted antifungal treatment with any antifungal drug (systemic or nonabsorbable) compared to placebo/no antifungal/any other antifungal in non‐neutropenic critically ill patients
Population: preventing fungal infections in non‐neutropenic critically ill patients
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Total (all‐cause) mortality Untargeted antifungal treatment with any antifungal drug (systemic or nonabsorbable) vs placebo/no antifungal/any other antifungal | RR 0.93 [0.79, 1.09] | 19 studies · 2374 participants | Moderate Downgraded: risk of bias |
Proven invasive fungal infection Untargeted antifungal treatment with any antifungal drug (systemic or nonabsorbable) vs placebo/no antifungal/any other antifungal | RR 0.57 [0.39, 0.83] | 17 studies · 2024 participants | Low Downgraded: risk of bias |
Superficial fungal infection Untargeted antifungal treatment with any antifungal drug (systemic or nonabsorbable) vs placebo/no antifungal/any other antifungal | RR 0.69 [0.37, 1.29] | 5 studies · 662 participants | Low Downgraded: risk of bias, imprecision, inconsistency, publication bias |
Fungal colonization Untargeted antifungal treatment with any antifungal drug (systemic or nonabsorbable) vs placebo/no antifungal/any other antifungal | RR 0.71 [0.52, 0.97] | 12 studies · 1030 participants | Low Downgraded: risk of bias, imprecision, inconsistency, publication bias |
Adverse events requiring cessation of study drug(s) Untargeted antifungal treatment with any antifungal drug (systemic or nonabsorbable) vs placebo/no antifungal/any other antifungal | RR 0.89 [0.62, 1.27] | 11 studies · 1691 participants | Low Downgraded: risk of bias |